Specifically, TRAIL treatment was associated with reduced cell survival in 3 of the 5 SCCHN cell lines tested and in all cases ZVAD was effective in partially reversing cytotoxicity. This evidence concerns the gene TNFSF10 and head and neck squamous cell carcinoma.